1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Factor VIII Inhibitors -Pipeline Insights, 2016

Factor VIII Inhibitors -Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “Factor VIII Inhibitors-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Factor VIII Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Factor VIII Inhibitors. DelveInsight’s Report also assesses the Factor VIII Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Factor VIII Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Factor VIII Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Factor VIII Inhibitors and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Factor VIII Inhibitors -Pipeline Insights, 2016

- Factor VIII Inhibitors Overview
- Factor VIII Inhibitors Disease Associated
- Factor VIII Inhibitors Pipeline Therapeutics
- Factor VIII Inhibitors Therapeutics under Development by Companies
- Factor VIII Inhibitors Filed and Phase III Products
- Comparative Analysis
- Factor VIII Inhibitors Phase II Products
- Comparative Analysis
- Factor VIII Inhibitors Phase I and IND Filed Products
- Comparative Analysis
- Factor VIII Inhibitors Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Factor VIII Inhibitors - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Factor VIII Inhibitors - Discontinued Products
- Factor VIII Inhibitors - Dormant Products
- Companies Involved in Therapeutics Development for Factor VIII Inhibitors
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Factor VIII Inhibitors by Therapy Area, 2016
- Number of Products under Development for Factor VIII Inhibitors, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Factor VIII Inhibitors Assessment by Monotherapy Products
- Factor VIII Inhibitors Assessment by Combination Products
- Factor VIII Inhibitors Assessment by Route of Administration
- Factor VIII Inhibitors Assessment by Stage and Route of Administration
- Factor VIII Inhibitors Assessment by Molecule Type
- Factor VIII Inhibitors Assessment by Stage and Molecule Type
- Factor VIII Inhibitors Therapeutics - Discontinued Products
- Factor VIII Inhibitors Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Factor VIII Inhibitors by Therapy Area, 2016
- Number of Products under Development for Factor VIII Inhibitors, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Factor VIII Inhibitors Assessment by Monotherapy Products
- Factor VIII Inhibitors Assessment by Combination Products
- Factor VIII Inhibitors Assessment by Route of Administration
- Factor VIII Inhibitors Assessment by Stage and Route of Administration
- Factor VIII Inhibitors Assessment by Molecule Type
- Factor VIII Inhibitors Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Von Willebrand Disease (Factor VIII Deficiency) Global Clinical Trials Review, H2, 2016

Von Willebrand Disease (Factor VIII Deficiency) Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • August 2016
  • by Global Data

Von Willebrand Disease (Factor VIII Deficiency) Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Von Willebrand Disease (Factor VIII Deficiency) Global Clinical Trials ...

PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2021

PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The global PEGylated proteins market is expected to USD 1,137.8 million by 2021 from USD 690.6 million in 2016, at a CAGR of 10.5% between 2016 and 2021. The growth of this market is mainly driven by increase ...

Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026: And other Rising Companies – a Market Report Assessing Developers and Producers of Those Competitor Biologics

Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026: And other Rising Companies – a Market Report Assessing Developers and Producers of Those Competitor Biologics

  • $ 2508
  • Industry report
  • April 2016
  • by Visiongain

Report Details Biosimilar Drug Producers – Your 2016 Guide to Companies’ Activities and Prospects Who are the most important and promising biosimilar drug companies? And what are their sales potentials? ...


Download Unlimited Documents from Trusted Public Sources

Global Blood Disease Statistics

  • October 2016
    68 pages
  • Blood Disease  

    Factor VIII  

  • World  

View report >

Global Biopharmaceutical Statistics

  • September 2016
    25 pages
  • Biopharmaceutic...  

  • Australia  

    World  

    Oceania  

View report >

Protein and Enzyme Industry in Poland

  • July 2016
    222 pages
  • Protein  

    Enzyme  

    Biotechnology  

  • Poland  

View report >

Global Therapy Market

9 months ago

Related Market Segments :

Factor VIII

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.